Biogen
NEWS
Regenxbio snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier this year.
Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.
Gilmore O’Neill, formerly Biogen’s senior vice president, late-stage clinical development, jumped ship and will be Sarepta Therapeutics’ chief medical officer.
Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
Alkermes, received a $50 million milestone payment from Biogen. The payment occurred after Biogen reviewed preliminary gastrointestinal tolerability data from an ongoing Phase III clinical trial for MS.
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
Since 2009 May 30 has been set aside as a day to raise awareness and campaign for an end to multiple sclerosis. The theme this year is focused on the research being conducted to develop a cure for the neurological disease.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
Educational institutions, even at the high school level, are creating specialized biotechnology training programs to satisfy the growth they see within the biotech industry.
JOBS
IN THE PRESS